Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

NCT07643831 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer

Interventions

DRUG: Giredestrant

Sponsor

Genentech, Inc.